What is claimed is:

1. Use of a composition consisting of guggulsterone and a pharmaceutically acceptable carrier in the manufacture of a medicament for the prevention or treatment of Parkinson's disease (PD).

2. Use of a composition consisting of guggulsterone and a pharmaceutically acceptable carrier in the manufacture of a medicament for the prevention of progression of PD.

3. Use of a composition consisting of guggulsterone and a pharmaceutically acceptable carrier in the manufacture of a medicament for the prevention or treatment of non-viral encephalopathy, amyotrophic lateral sclerosis (ALS), Huntington's disease or multiple sclerosis (MS).